Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:daratumumab
hyaluronidase-fihj |
| gptkbp:approvalYear |
2020-05-01
|
| gptkbp:ATCCode |
L01XC24
|
| gptkbp:brand |
daratumumab and hyaluronidase-fihj
|
| gptkbp:combines |
gptkb:carfilzomib
gptkb:dexamethasone gptkb:lenalidomide gptkb:bortezomib gptkb:pomalidomide |
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
combination drug
|
| https://www.w3.org/2000/01/rdf-schema#label |
Darzalex Faspro
|
| gptkbp:indication |
multiple myeloma
light chain amyloidosis |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Janssen_Biotech
|
| gptkbp:mechanismOfAction |
CD38-directed cytolytic antibody
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
gptkb:pneumonia
gptkb:hypercalcemia gptkb:anemia bronchitis nausea vomiting diarrhea constipation fatigue headache hypertension back pain cough peripheral neuropathy chills rash hypokalemia insomnia neutropenia thrombocytopenia dyspnea arthralgia hyperglycemia hyperkalemia upper respiratory tract infection nasopharyngitis pyrexia hypomagnesemia hypophosphatemia hyperphosphatemia hypocalcemia peripheral edema musculoskeletal pain infusion-related reactions hypermagnesemia |
| gptkbp:bfsParent |
gptkb:Darzalex
|
| gptkbp:bfsLayer |
6
|